The Effects of Perioperative Anesthesia and Analgesia on Immune Function in Patients Undergoing Breast Cancer Resection: A Prospective Randomized Study by 援щ낯�� et al.
Int. J. Med. Sci. 2017, Vol. 14 
 
 
http://www.medsci.org 
970 
International Journal of Medical Sciences 
2017; 14(10): 970-976. doi: 10.7150/ijms.20064 
Research Paper 
The Effects of Perioperative Anesthesia and Analgesia on 
Immune Function in Patients Undergoing Breast Cancer 
Resection: A Prospective Randomized Study 
Jin Sun Cho1*, Mi-Hyang Lee2, 3*, Seung Il Kim4, Seho Park4, Hyung Seok Park4, Ein Oh1, Jong Ho Lee2, 5, 6, 
and Bon-Nyeo Koo1 
1. Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea; 
2. National Leading Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Department of Food and Nutrition, College of Human Ecology, Yonsei University, 
Seoul, Republic of Korea; 
3. Korea Ginseng Corporation Research Institute, Korea Ginseng Corporation, Daejeon, Republic of Korea; 
4. Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea; 
5. Department of Food and Nutrition, Brain Korea 21 PLUS Project, College of Human Ecology, Yonsei University, Seoul, Republic of Korea; 
6. Research Center for Silver Science, Institute of Symbiotic Life-TECH, Yonsei University, Seoul, Republic of Korea. 
* Jin Sun Cho and Mi-Hyang Lee are co-first authors.  
 Corresponding authors: Jong Ho Lee, Department of Food and Nutrition, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea Fax: 
+82-2-364-2951/ Tel: +82-2-2123-8385/ E-mail: jhleeb@younsei.ac.kr Bon-Nyeo Koo, Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research 
Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea Fax: +82-2-364-2951/ Tel: +82-2-2227-3835/ E-mail: 
koobn@yuhs.ac 
© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license 
(https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. 
Received: 2017.03.14; Accepted: 2017.06.18; Published: 2017.08.18 
Abstract 
Introduction: Perioperative anesthesia and analgesia exacerbate immunosuppression in 
immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor 
immunity. We compared the effects of two different anesthesia and analgesia methods on the NK cell 
cytotoxicity (NKCC) in patients undergoing breast cancer surgery. 
Methods: Fifty patients undergoing breast cancer resection were randomly assigned to receive 
propofol-remifentanil anesthesia with postoperative ketorolac analgesia (Propofol-ketorolac groups) or 
sevoflurane-remifentanil anesthesia with postoperative fentanyl analgesia (Sevoflurane-fentanyl group). 
The primary outcome was NKCC, which was measured before and 24 h after surgery. Post-surgical 
pain scores and inflammatory responses measured by white blood cell, neutrophil, and lymphocyte 
counts were assessed. Cancer recurrence or metastasis was evaluated with ultrasound and whole body 
bone scan every 6 months for 2 years after surgery. 
Results: The baseline NKCC (%) was comparable between the two groups (P = 0.082). Compared with 
the baseline value, NKCC (%) increased in the Propofol-ketorolac group [15.2 (3.2) to 20.1 (3.5), P = 
0.048], whereas it decreased in the Sevoflurane-fentanyl group [19.5 (2.8) to 16.4 (1.9), P = 0.032]. The 
change of NKCC over time was significantly different between the groups (P = 0.048). Pain scores 
during 48 h after surgery and post-surgical inflammatory responses were comparable between the 
groups. One patient in the Sevoflurane-fentanyl group had recurrence in the contralateral breast and no 
metastasis was found in either group.  
Conclusions: Propofol anesthesia with postoperative ketorolac analgesia demonstrated a favorable 
impact on immune function by preserving NKCC compared with sevoflurane anesthesia and 
postoperative fentanyl analgesia in patients undergoing breast cancer surgery. 
Key words: anesthesia; analgesia; breast cancer; immunity; natural killer cell. 
Introduction 
Surgical resection is one of the primary 
treatments for solid tumors, but the dissemination of 
tumor cells into the blood and lymphatic systems 
inevitably occurs during surgery. Whether the 
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residual tumor cells lead to clinical deterioration 
depends on the balance between perioperative factors 
promoting cancer survival and growth and the host’s 
anti-tumor defenses [1]. Surgery-related 
neuroendocrine stress responses, anesthetics, and 
opioid analgesics are factors known to adversely 
affect the anti-tumor immune defenses [2]. 
 Natural killer (NK) cells are a critical part of 
innate immunity, acting as the main defense against 
the spread of cancer [3]. Reduced NK cell cytotoxicity 
(NKCC) is associated with poor cancer prognosis in 
breast, colon, and prostate cancers [4-6]. Especially in 
breast cancer patients, the level of NKCC is inversely 
correlated with the stage and metastasis of cancer [4]. 
 To date, there have been few prospective studies 
comparing the effects of perioperative anesthetic and 
analgesic agents on NKCC in patients undergoing 
cancer surgery. Previous experimental studies have 
shown both detrimental and protective effects of 
certain anesthetics and analgesics on immune 
function. Volatile anesthetic agents, including 
sevoflurane and desflurane, decreased NKCC [7], 
whereas propofol did not suppress NKCC [8]. 
Fentanyl suppressed NK cell function [9], whereas 
non-steroidal anti-inflammatory drugs (NASIDs) 
reversed NKCC suppression [10]. Based on these 
results, we hypothesized that avoiding volatile 
anesthetics and opioid analgesics might attenuate the 
immunosuppression in the perioperative periods. In 
this prospective randomized study, we compared the 
effects of two different anesthetic and analgesic 
methods on NKCC in patients undergoing breast 
cancer surgery.  
Patients and Methods 
This study was approved by the Institutional 
Review Board and Hospital Research Ethics 
Committee of Severance Hospital, Yonsei University 
Health System, Seoul, Korea, on February 2014 
(#4-2013-0937). It was registered at clinicaltrial.gov on 
March 2014 (NCT02089178). Patients (20-65 years old) 
who underwent elective surgery for breast cancer and 
had an American Society of Anesthesiologists (ASA) 
physical status classification of I to III were included. 
The exclusion criteria were renal or hepatic 
impairment, a body mass index > 35 kg/m2, 
immunosuppressive therapy, immune disorders, 
steroid administration within the last six months, 
metastasis, or radiotherapy or chemotherapy before 
surgery. Written formed consent was obtained from 
all of patients. A total of 50 patients were randomly 
assigned into one of the study groups (25 patients 
each) using a computer-generated random number 
table. In the Propofol-ketorolac group, patients were 
anesthetized with propofol and remifentanil and 
received ketorolac after surgery. In the Sevo-fentanyl 
group, patients were anesthetized with sevoflurane 
and remifentanil and received fentanyl 
postoperatively. Assignments were concealed in 
sealed envelopes and the randomization was not 
stratified or blocked. 
 In the operating theatre, patients received 
glycopyrrolate 0.2 mg and were applied with routine 
ASA monitoring, including electrocardiography, 
peripheral oxygen saturation, and blood pressure. 
Before anesthetic induction, a peripheral venous 
cannula was inserted to obtain a blood sample before 
and after surgery. In the Propofol-ketorolac group, 
propofol was administered using a target-controlled 
infusion (Orchestra®Base Primea, Fresenius Vial, 
Sévres, France) with the modified Marsh model. A 
target plasma concentration of propofol was 4 μg/ml 
initially, and then adjusted in 0.2 μg/ml increments. 
In the Sevo-fentanyl group, anesthesia was induced 
with propofol 1.5 to 2 μg/kg and maintained with 
sevoflurane. The concentrations of propofol and 
sevoflurane were titrated to maintain the bispectral 
index score in the range of 40-60. In addition to 
anesthetic agents, remifentanil was infused in both 
groups to maintain hemodynamic stability 
intraoperatively. Low-dose remifentanil infusion did 
not impair NKCC [11]. Remifentanil was infused 
using a target-controlled infusion to achieve an 
effect-site concentration of 1.5 ng/ml at induction and 
then between 3 and 5 ng/ml for maintenance. 
Rocuronium 0.6 mg/kg was administered to facilitate 
tracheal intubation. Mean blood pressure and heart 
rate were maintained within 25% of baseline. At the 
end of the surgery, all patients received neostigmine 
40 μg/kg and glycopyrrolate 5 μg/kg for reversal of 
neuromuscular block and ramosetron 0.3 mg for 
postoperative nausea and vomiting prophylaxis. At 
the end of surgery, the Propofol-ketorolac group 
received ketorolac 60 mg and the Sevo-fentanyl group 
received fentanyl 50 μg for acute pain relief.  
 The primary aim was to compare the effects of 
two anesthetic and analgesic methods on the immune 
function assessed by NKCC, measured preoperatively 
and at 24 h postoperatively. Other outcome measures 
included postoperative pain scores, IL-2 levels, and 
inflammatory responses assessed by white blood cell, 
neutrophil, and lymphocyte counts. The incidence of 
cancer recurrence or metastasis was evaluated with a 
breast ultrasound, abdomen ultrasound, and whole 
body bone scan every 6 months after surgery. 
Assay for natural killer cell cytotoxicity   
Blood samples were obtained before and at 24 h 
after surgery. Whole blood was mixed with the same 
volume of RPMI 1640 (Gibco, Invitrogen Co, USA), 
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and the mixture was laid on Histipaque®-1077 (Sigma, 
CA, USA) and centrifuged (2000 rpm for 20 min at 
10°C). Then, a thin layer of peripheral blood 
mononuclear cells (PBMCs) was harvested, washed 
twice with RPMI 1640, and resuspended in RPMI 1640 
containing streptomycin. NKCC was assessed using 
the CytoTox 96® Non-Radioactive Cytotoxicity Assay 
Kit (Promega Co., WI, USA). This colorimetric assay 
quantitatively measures lactate dehydrogenase 
(LDH), a stable cytosolic enzyme that is released upon 
cell lysis, in much the same way that 51Cr is released in 
a radioactive assay. PBMCs (effector cell) and K562 
cells (targeted cell; 2 x 104 cells/well) were seeded in 
the well in a ratio of 1.25:1 and incubated overnight at 
37°C in 5% CO2. Finally, the NKCC of effector cells 
was measured with a 2030 multilabel reader (VictorTM 
X5, PerkinElmer, MA, USA) at 490 nm, and the 
cytotoxicity percentage was calculated with as [12]:  
% Cytotoxicity = [(Experimental – Effector 
Spontaneous – Target Spontaneous) / (Target 
Maximum – Target Spontaneous)] x 100 
The maximum LDH release from target cells was 
measured by using the lysis solution (Triton® X-100), 
which should yield complete lysis of target cells and 
subsequent release of cytoplasmic LDH into the 
surrounding culture medium. 
Assay for interleukin-2  
IL-2 was measured in serum using a commercial 
ELISA kit (Quantikine Human IL-2 ELISA Kit; R&D 
System Inc., MN, USA) preoperatively and at 24 h 
after surgery. The absorbance was read at 450 nm 
using a Spectra Max 190 micro-plate reader 
(Molecular Devices, CA, USA).  
Pain scores 
Pain scores were assessed using a 11-point 
numerical rating scale (NRS, 0 = no pain to 10 = worst 
pain) at postoperative 30 min, 6 h, 24 h, and 48 h. For 
immediate postoperative analgesia, the 
Propofol-ketorolac group received ketorolac 60 mg 
and the Sevo-fentanyl group received fentanyl 50 μg 
at the end of surgery. In the post-anesthesia care unit, 
propacetamol 2 g in the Propofol-ketorolac group or 
fentanyl 50 μg in the Sevo-fentanyl group was 
available as an additional analgesic for patients with a 
NRS ≥ 4. In the ward, both groups received tramadol 
50 mg as a rescue analgesic, which does not suppress 
NKCC [13]. 
Statistics 
No previous study was available to inform 
assumptions regarding changes of NKCC following 
two different anesthetic and analgesic methods. We 
calculated a sample size based on preliminary results 
for the first five patients of each group, and estimated 
that 22 patients in each group would be required to 
detect a mean difference of 10% and standard 
deviation of 10% in the NKCC after surgery with 90% 
power at a significance of P < 0.05. We factored in a 
10% dropout rate and enrolled 25 patients in each 
group.  
 Statistical analyses were performed with IBM 
SPSS 20.0 (IBM Corp., Armonk, NY, USA) and SAS 9.2 
(SAS Institute Inc., Cary, NC, USA). Continuous 
variables were analyzed with the independent t-test 
or Mann-Whitney U test, after testing for normality of 
distribution using Kolmogorov-Smirnov test. 
Categorical variables were analyzed with χ2 test or 
Fisher exact test. Variables measured repeatedly, such 
as NKCC, IL-2, total leukocyte, neutrophil, and 
lymphocyte counts, and neutrophil-lymphocyte-ratio 
(NLR) were analyzed with a linear mixed model, with 
patient indicator as a random effect and with group, 
time, and group-by-time as fixed effects. The 
group-by-time interaction assesses whether the 
change over time differs between groups. Post-hoc 
analyses with the Bonferroni correction were 
performed for multiple comparisons when variables 
with repeated measures showed significant 
differences between groups. A P value < 0.05 was 
considered statistically significant. 
Results 
Of 50 patients enrolled, one patient in each 
group was eliminated due to concurrent breast 
reconstruction surgery. The remaining 48 patients 
completed the study without any complications. 
Patient characteristics and operation details were 
comparable between the two groups (Table 1).  
Natural killer cell cytotoxicity 
The baseline NKCC (%) was not statistically 
different between the two groups (P = 0.082). 
Compared to the baseline, NKCC (%) increased after 
surgery in the Propofol-ketorolac group [mean (SEM) 
preoperative to postoperative; 15.2 (3.2) to 20.1 (3.5), P 
= 0.048], whereas it decreased in the Sevo-fentanyl 
group [19.5 (2.8) to 16.4 (1.9), P = 0.032]. The change of 
NKCC over time was significantly different between 
the groups (P = 0.048) (Figure 1). 
Serum concentration of interleukin-2   
No significant postoperative change was seen in 
IL-2 levels in either group [median (IQR) preoperative 
to postoperative; 2.75 (1.61, 4.97) to 3.16 (1.97, 5.52), P 
= 0.721 in the Propofol- ketorolac group, and 2.65 
(2.15, 3.96) to 2.81 (2.00, 4.62), P = 0.523 in the Sevo- 
fentanyl group]. The change of IL-2 levels over time 
was not significant between the groups (P = 0.620).  
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Table 1. Patient characteristics and operation details 
Variables Propofol-ketorolac group 
(n = 24) 
Sevo-fentanyl group 
(n = 24) 
P value 
Age (years) 55.4 ± 7.0 55.7 ± 12.9  0.923 
BMI (kg/m2) 23.6 ± 3.0 24.3 ± 3.7 0.500 
ASA class II/III 9/ 0 6/ 3 0.165 
Type of surgery   0.360 
  Partial mastectomy 7 11  0.233 
  Total mastectomy 14 12 0.562 
  Radical mastectomy  3 1 0.296 
Lymph node involvement    
  Positive/ negative 13 / 11 10 / 14 0.386 
Duration of operation (min) 101.6 ± 30.9 99.7 ± 33.0  0.841 
Duration of anesthesia (min) 132.8 ± 28.2 127.0 ± 34.7  0.535 
Dose of remifentanil (μg/kg/min) 0.09 ± 0.02 0.08 ± 0.02 0.082 
Values are mean ± standard deviation or number.  
Propofol-ketorolac group, propofol-remifentanil anesthesia and postoperative ketorolac analgesia group; Sevo-fentanyl group, sevoflurane-remifentanil anesthesia and 
postoperative fentanyl analgesia group; BMI, body mass index; ASA class, American Society of Anesthesiologists physical status classification. 
 
 
 
 
Figure 1. Natural killer cell cytotoxicity before and after surgery NK cell, natural killer cell; Propofol-ketorolac group, propofol-remifentanil anesthesia and 
postoperative ketorolac analgesia group; Sevo-fentanyl group, sevoflurane-remifentanil anesthesia and postoperative fentanyl analgesia group. The change of NK cell 
cytotoxicity over time was significantly different between the groups (P Group x Time = 0.048). 
 
Inflammatory response 
The changes of the total leukocyte, neutrophil, 
and lymphocyte counts and NLR over time were not 
significant between the groups (Table 2). Lymphocyte 
counts after surgery decreased in both groups 
compared to the baseline, but the difference was 
significant only in the Sevo-fentanyl group (P = 0.037).  
Pain score  
Pain scores during the postoperative 48 h were 
comparable between the two groups. In the 
post-anesthesia care unit, 8 patients in the 
Propofol-ketorolac group received propacetamol and 
12 patients in the Sevo-fentanyl group received 
fentanyl as an additional analgesic. The number of 
patients requiring tramadol in the ward and total 
doses given were comparable between two groups 
(Table 3).  
Postoperative outcomes 
One patient in the Sevo-fentanyl group had 
recurrence in the contralateral breast 18 months after 
surgery, and underwent a partial mastectomy. No 
patient had metastasis in either group within two 
years after surgery. 
Discussion 
During breast cancer surgery, patients who 
received propofol-remifentanil anesthesia and 
postoperative ketorolac analgesia exhibited preserved 
NKCC compared with those who received 
sevoflurane-remifentanil anesthesia and 
postoperative fentanyl analgesia. Postoperative 
inflammatory responses and the incidences of 
short-term cancer recurrence and metastasis were not 
different between the two anesthetic and analgesic 
methods. 
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Table 2. Total leukocyte, neutrophil, and lymphocyte counts  
Variables Time points Propofol-ketorolac group (n = 24) Sevo-fentanyl group (n = 24) P Groupⅹ Time 
Leukocyte 
(10-3/μL) 
before surgery 6.05 ± 1.47 6.83 ± 1.43 0.996 
at 24 h after surgery 7.78 ± 1.62 * 8.57 ± 1.88 * 
Neutrophil 
(10-3/μL) 
before surgery 3.37 ± 1.27 4.09 ± 1.07 0.988 
at 24 h after surgery 5.41 ± 1.35 * 6.13 ± 1.56 * 
Lymphocyte 
(10-3/μL) 
before surgery 1.99 ± 0.51 2.15 ± 0.71  0.538 
at 24 h after surgery 1.74 ± 0.51 1.75 ± 0.66 * 
Neutrophil to lymphocyte ratio before surgery 1.76 ± 0.69 2.13 ± 1.08 0.841 
at 24 h after surgery 3.37 ± 1.27 * 3.85 ± 1.46 * 
Values are mean ± standard deviation.  
Propofol-ketorolac group, propofol-remifentanil anesthesia and postoperative ketorolac analgesia group; Sevo-fentanyl group, sevoflurane-remifentanil anesthesia and 
postoperative fentanyl analgesia group; PGroup × Time, P-value for the group × time interaction in the linear mixed model.  
The baseline values were not different between the two groups. * P < 0.05 vs. before surgery.  
Table 3. Pain scores and additional analgesic requirements 
 Propofol-ketorolac group (n = 24) Sevo-fentanyl group (n = 24) P value 
Pain score    
at post-op 30 min  2.8 ± 0.8 2.7 ± 0.6 0.476 
at post-op 6 h  2.2 ± 0.7 2.3 ± 1.1 0.642 
at post-op 24h  1.9 ± 0.6 2.1 ± 0.7 0.315 
at post-op 48 h  1.6 ± 0.7 1.6 ± 0.8 0.941 
Worst pain score    
during post-op 30 min  4.0 ± 1.5  4.0 ± 1.4 0.923 
during post-op 30 min–6 h  4.3 ± 1.9 5.0 ± 2.5 0.271 
during post-op 6–24 h  2.5 ± 1.3 3.3 ± 1.7 0.104 
during post-op 24–48 h  1.9 ± 0.4 2.0 ± 1.0 0.828 
Analgesic drugs    
  at the end of surgery (ketorolac, mg) (n) * 60 (24) 0 >0.999 
                   (fentanyl, μg) (n) * 0 50 (24) >0.999 
during post-op 30 min (propacetamol, g) (n) * 2 (8) 0 >0.999 
                  (fentanyl, μg) (n)* 0 75.0 ± 39.9 (12) >0.999  
during post-op 30 min–6 h (tramadol, mg) (n)* 47.9 ± 7.2 (12) 53.8 ± 13.9 (13) 0.199 (0.773) 
during post-op 6–24 h (tramadol, mg) (n) * 45.0 ± 11.2 (5) 60.0 ± 22.4 (5) 0.217 (>0.999) 
during post-op 24–48 h (tramadol, mg) (n) * 0 50 (1) 0.35 (0.75) 
Values are mean ± standard deviation or number. 
Propofol-ketorolac group, propofol-remifentanil anesthesia and postoperative ketorolac analgesia group; Sevo-fentanyl group, sevoflurane-remifentanil anesthesia and 
postoperative fentanyl analgesia group; post-op, postoperative; Pain score, a numerical pain intensity scale (0 = no pain, 10 = the worst pain); (n)*, number of patients 
requiring analgesic drugs. 
 
 
 Compelling clinical and experimental evidences 
have suggested that surgery and anesthesia cause a 
transient period of immunosuppression, which may 
encourage both the implantation of surgically 
disseminated neoplastic cells and the growth of 
existing micro-metastases [1, 2]. Anesthesia can 
interact with the immune system, facilitating or 
hindering tumor growth and metastasis. NK cells, 
CD3- CD56+ lymphocytes, have direct cellular 
cytotoxicity against tumor cells and act as the body’s 
main defense against local tumor growth and 
metastasis.[1, 3] Patients diagnosed with breast cancer 
have inhibition and significantly lower levels of 
NKCC than do healthy patients. Furthermore, 
patients with more advanced breast cancer (stage 4) 
have an increased proportion of immature and 
non-cytotoxic NK cells in the blood than those with 
stage 1-3 [4].  
 Anesthetic agents have exhibited different 
effects on NKCC in animal and human studies. 
Propofol preserved NKCC and cytotoxic T 
lymphocyte activity and suppressed tumor growth.[8, 
14] Propofol has cyclooxygenase (COX)-2 inhibiting 
activity, reducing the production of prostaglandin E2 
(PGE2), a mediator of pain and inflammation that 
inhibits NKCC [15]. In contrast that propofol has only 
minor effects on NK cells at clinically relevant 
concentrations, volatile anesthetics have the dose- and 
time-dependent suppressive effects on NK cells and T 
lymphocytes. Isoflurane [16], sevoflurane [7], and 
desflurane [7] were demonstrated to suppress NKCC. 
In a rat model of lung tumor, halothane reduced 
NKCC and increased lung tumor retention and 
metastases, whereas propofol preserved NKCC [8]. 
These attributes of propofol and sevoflurane are 
consistent with our results, which showed increased 
NKCC in the Propofol-ketorolac group and decreased 
NKCC in the Sevo-fentanyl group.  
 Both pain and opioid analgeiscs are known to 
cause immunosuppression [1, 2]. Fentanyl and 
morphine depressed NK cell function and markedly 
increased tumor burden, whereas ketorolac reversed 
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NKCC suppression [9, 10]. NSAIDs inhibit 
prostaglandin synthesis via inhibition of the COX 
enzyme and COX-2 inhibitors have anti-tumor and 
anti-angiogenic properties [17]. As our two groups 
showed comparable analgesic efficacies, the impact of 
pain on immune function should have been the same 
in both groups, eliminating pain as a contributing 
factor to different NKCC between the groups. 
Therefore, immunosuppressive effect of fentanyl 
might contribute to decreased NKCC in the 
Sevo-fentanyl group compared with preseved NKCC 
in the Propofol-ketorolac group.  
 Antitumor responses in NKCC are activated by 
various cytokines; and among those, IL-2 is an 
important activator of NK cells [18]. IL-2 
administration reversed the NKCC suppression 
associated with surgery and significantly decreased 
tumor incidence in an animal model [10]. In addition, 
IL-2 activated human NK cells, effectively killing 
colon carcinoma, in vitro [19]. We assessed IL-2 level 
to exclude the possibility of different IL-2 level 
between the groups before surgery and investigate if 
NKCC change after surgery would be associated with 
IL-2 change. We observed the significant increase of 
IL-2 in both groups after surgery compared to before 
surgery, but no significant difference was found 
between the two groups.  
 Anesthetic and analgesic agents may affect the 
concentrations of immunocompetent cells, resulting 
in lymphopenia and neutrophilia [20]. A high NLR is 
considered as a prognostic indicator for breast cancer 
[21]. Suppression of lymphocytes is proportional to 
the dose and duration of anesthetics use. Volatile 
anesthetics increased the neutrophil and decreased 
the lymphocyte [7, 22], and propofol also decreased 
peripheral lymphocytes counts by reducing 
proliferative responses of lymphocytes [23]. However, 
propofol provided more effective protection for 
circulating lymphocytes than sevoflurane [24]. 
Fentanyl induced a time-dependent apoptosis of 
lymphocytes [25], and flurbiprofen showed similar 
effects on lymphocyte level compared with fentanyl 
[26]. In the present study, the neutrophil count and 
NLR increased significantly after surgery in both 
groups, whereas the lymphocyte decreased 
significantly only in the Sevo-fentanyl group. Our 
findings suggest that sevoflurane and fentanyl 
induced more suppressive effect on lymphocytes 
compared to propofol and ketorolac.  
 As detrimental effects of volatile anesthesia and 
opioids on immune function have been identified, 
regional anesthesia has been tried in an attempt to 
reduce volatile anesthetics or opioid use. In breast 
cancer surgery, patients who received propofol and 
paravertebral block showed preserved NKCC 
compared to those who received sevoflurane and 
opioids [27]. However, the addition of spinal blockade 
to halothane did not attenuate NKCC suppression 
compared to halothane anesthesia alone or combined 
with systemic morphine [28]. A recent meta-analysis 
showed no association between regional anesthesia 
and NK cell function [29]. Whereas there are 
contraindications such as coagulopathy or 
inflammation and the possibility of failure to perform 
regional anesthesia, intravenous or volatile anesthesia 
can be performed with little difficulties and few 
contraindications. Considering the effects on immune 
function, the anesthetic agent of choice in cancer 
surgery would be propofol rather than volatile 
anesthetics. In addition, non-opioid analgesics may be 
ideal for the restoration of perioperative immune 
competence rather than opioid. 
 Our study has some limitations. First, due to the 
study design, the operating room staff could not be 
blinded to the group allocation. However, the 
investigators who conducted follow-ups 
postoperatively, including analysis of laboratory 
findings and assessments of pain intensity, were 
completely unaware of the patient’s group 
assignment. Second, we used remifentanil for 
intraoperative hemodynamic stability and tramadol 
for postoperative pain control in both groups. 
Although remifentanil and tramadol did not impair 
NKCC [11, 13] and the doses were comparable 
between the groups in the present study, the possible 
impacts of remifentanil and tramadol on NKCC 
cannot be excluded. Third, we could not discriminate 
the respective effects of each drug on NKCC and 
inflammatory responses. The differences of 
postoperative NKCC between the groups might be 
attributed to the combined effects of 
propofol-ketorolac and sevoflurane-fentanyl. Forth, 
we used PBMCs as effector cells instead of isolating 
NK cells. Although NK cell proportion varies 
individually, the cytotoxic activity of PBMC and 
separated NK cell samples was reported to be 
correlated, indicating that both PBMC and separated 
NK cell measurement methods are equally effective 
tools for investigation of NK cell activity [30]. NKCC 
using PBMC can provide natural circumstance like in 
vivo environment [31]. Last, although cancer 
metastasis within two year after surgery did not occur 
in the present study, further evaluation of long-term 
outcomes are needed to make a conclusion about 
cancer recurrence or metastasis. 
 In conclusion, propofol anesthesia and 
postoperative ketorolac analgesia in breast cancer 
surgery demonstrated a better effect on the immune 
function by preserving NKCC compared to 
sevoflurane anesthesia and postoperative fentanyl 
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analgesia. The findings of the present study are 
consistent with the hypothesis that avoiding volatile 
anesthetics and opioids could reduce the 
immunosuppression during surgery. Careful 
selection of anesthetic and analgesic agents may 
influence immune functions and postoperative 
outcomes. Further studies to find anesthetic and 
analgesic methods which mitigate immune-
suppression in cancer surgery are warranted.  
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